Dataset Information


SRC1 gene regulation in endocrine resistant breast cancer cells

ABSTRACT: The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the development of a steroid independent tumour. The p160 steroid coactivator protein SRC-1, through interactions with developmental proteins and other non-steroidal transcription factors drives this tumour adaptability. Here, using discovery studies we identify ADAM22, a non-protease member of the ADAMs family, as a direct target of SRC-1, independent of estrogen receptor(ER). Molecular, cellular, in vivo and clinical studies confirmed SRC-1 as a regulator of ADAM22 and established a role for ADAM22 in endocrine resistant tumour progression. ADAM22 has the potential to act as a therapeutic drug target and a companion predictive biomarker in the treatment of endocrine resistant breast cancer. Overall design: 14 samples representing 4 conditions were analysed. Samples were transfected with either a siRNA targetting SRC1 or a control scrambled siRNA. Samples were subject to tamoxifen treatment or untreated.

INSTRUMENT(S): [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

ORGANISM(S): Homo sapiens  


PROVIDER: GSE28645 | GEO | 2012-01-11



Similar Datasets

2012-01-11 | E-GEOD-28645 | ArrayExpress
2011-11-01 | E-GEOD-28987 | ArrayExpress
| GSE99647 | GEO
| GSE99648 | GEO
2018-10-23 | GSE121584 | GEO
2014-01-14 | E-GEOD-54027 | ArrayExpress
| GSE71347 | GEO
2010-01-01 | GSE17775 | GEO
2013-04-10 | MTBLS30 | MetaboLights
2010-05-16 | E-GEOD-17775 | ArrayExpress